Antirelapse efficacy of various primaquine regimens for Plasmodium vivax

Malaria Research and Treatment

Volumn 2014, Issue , 2014, Pages

  Rajgor, D D ^a   Gogtay, N J ^a   Kadam, V S ^a   Kocharekar, M M ^a   Parulekar, M S ^a   Dalvi, S S ^a   Vaidya, A B ^b   Kshirsagar, N A ^c,d  

^a KEM HOSPITAL   (India)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^d Department of Pediatrics   (India)

Author keywords

[No Author keywords available]

Indexed keywords

PRIMAQUINE;

ABDOMINAL PAIN; ADULT; ANTIMALARIAL DRUG RESISTANCE; ANTIRELAPSE ACTIVITY; ARTICLE; BURNING SENSATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIGASTRIC BURNING; EPIGASTRIC PAIN; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PLASMODIUM VIVAX MALARIA; POLYMERASE CHAIN REACTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; REINFECTION; RELAPSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VOMITING; WEAKNESS;

EID: 84953754672     PISSN: 20908075     EISSN: 20444362     Source Type: Journal    
DOI: 10.1155/2014/347018     Document Type: Article

References (41)

1. V. P. Sharma, "Re-emergence of malaria in India," Indian Journal of Medical Research, vol. 103, pp. 26-45, 1996.
2. A. Kumar, N. Valecha, T. Jain, and A. P. Dash, "Burden of malaria in India: retrospective and prospective view," The American Journal of Tropical Medicine and Hygiene, vol. 77, no. 6, pp. 69-78, 2007.
3. J. A. Newton Jr., G. A. Schnepf, M. R. Wallace, H. O. Lobel, C. A. Kennedy, and E. C. Oldfield III, "Malaria in US marines returning from Somalia," The Journal of the American Medical Association, vol. 272, no. 5, pp. 397-399, 1994.
4. J. E. Svenson, J. D. MacLean, T.W. Gyorkos, and J. Keystone, "Imported malaria: clinical presentation and examination of symptomatic travelers," Archives of Internal Medicine, vol. 155, no. 8, pp. 861-868, 1995.
5. S. Mali, K. R. Tan, and P. M. Arguin, "Malaria surveillance-United States, 2009," MMWR Surveillance Summaries, vol. 60, pp. 1-15, 2011.
6. G. S. Dow, W. F. McCarthy, M. Reid, B. Smith, D. Tang, and G. D. Shanks, "A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malariaendemic area," Malaria Journal, vol. 13, article 49, 2014.
7. A. Llanos-Cuentas, M. V. Lacerda, R. Rueangweerayut et al., "Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study," The Lancet, vol. 383, pp. 1049-1058, 2013.
8. H. Liu, H. L. Yang, J.W. Xu, J. Z. Wang, R.H. Nie, and C. F. Li, "Artemisinin-naphthoquine combination versus chloroquineprimaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China," Malaria Journal, vol. 12, article 409, 2013.
9. K. Na Bangchang, W. Songsaeng, A. Thanavibul, P. Choroenlarp, and J. Karbwang, "Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 88, no. 2, pp. 220-222, 1994.
10. L. Bruce-Chwatt, R. Black, C. Canfield, D. Clyde, W. Peters, and W. Werns-dorfer, Chemotherapy of Malaria, WorldHealth Organization, Geneva, Switzerland, 2nd edition, 1981.
11. D. Bunnag, J. Karbwang, A. Thanavibul et al., "High dose of primaquine in primaquine resistant vivaxmalaria," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 88, no. 2, pp. 218-219, 1994.
12. B. L. Smoak, R. F. deFraites, A. J. Magill, K. C. Kain, and B. T. Wellde, "Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia, "The American Journal of Tropical Medicine and Hygiene, vol. 56, no. 2, pp. 231-234, 1997.
13. T. Leslie, I. Mayan, N. Mohammed et al., "A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan," PLoS ONE, vol. 3, no. 8, Article ID e2861, 2008.
14. D. D. Rajgor, N. J. Gogtay, V. S. Kadam et al., "Efficacy of a 14-day primaquine regimen in preventing relapses in patients with Plasmodium vivax malaria in Mumbai, India," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 97, no. 4, pp. 438-440, 2003.
15. C. F. Golenda, J. Li, and R. Rosenberg, "Continuous in vitro propagation of the malaria parasite Plasmodium vivax," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 13, pp. 6786-6791, 1997.
16. K. Chotivanich, K. Silamut, R. Udomsangpetch et al., "Ex-vivo short-term culture and developmental assessment of Plasmodiumvivax," Transactions of the Royal Society of TropicalMedicine and Hygiene, vol. 95, no. 6, pp. 677-680, 2001.
17. A. Voorberg-van derWel, A. Zeeman, S. M. van Amsterdam et al., "Transgenic fluorescent Plasmodium cynomolgi liver stages enable live imaging and purification of Malaria hypnozoiteforms," PLoS ONE, vol. 8, no. 1, Article ID e54888, 2013.
18. G. Snounou and H. Beck, "The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment," Parasitology Today, vol. 14, no. 11, pp. 462-467, 1998.
19. "Chemotherapy of malaria and resistance to antimalarials. Report of aWHO scientific group, "World Health Organization Technical Report Series, vol. 529, pp. 1-121, 1973.
20. W. H. Wernsdorfer, D. Payne, and I. McGregor, "Drug sensitivity tests inmalaria parasites," in Malaria. Principles and Practice ofMalariology, W. H. Wernsdorfer and I. A. McGregor, Eds., pp. 1765-1800, Churchill Livingstone, Edinburgh, UK, 1988.
21. T. Adak, V. P. Sharma, and V. S. Orlov, "Studie on the Plasmodium vivax relapse pattern in Delhi, India," American Journal of Tropical Medicine and Hygiene, vol. 59, no. 1, pp. 175-179, 1998.
22. M. C. Bruce, M. R. Galinski, J. W. Barnwell, G. Snounou, and K. P. Day, "Polymorphism at the merozoite surface protein-3α locus of Plasmodium vivax: global and local diversity," The American Journal of Tropical Medicine and Hygiene, vol. 61, no. 4, pp. 518-525, 1999.
23. J. C. Rayner, C. S. Huber, D. Feldman, P. Ingravallo, M. R. Galinski, and J. W. Barnwell, "Plasmodium vivax merozoite surface protein PvMSP-3β is radically polymorphic through mutation and large insertions and deletions," Infection, Genetics and Evolution, vol. 4, no. 4, pp. 309-319, 2004.
24. M. Imwong, G. Snounou, S. Pukrittayakamee et al., "Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites," Journal of Infectious Diseases, vol. 195, no. 7, pp. 927-933, 2007.
25. A. A. Craig and K. C. Kain, "Molecular analysis of strains of Plasmodium vivax frompaired primary and relapse infections," Journal of Infectious Diseases, vol. 174, no. 2, pp. 373-379, 1996.
26. N. J. Gogtay, S. Desai, K. D. Kamtekar, V. S. Kadam, S. S. Dalvi, and N. A. Kshirsagar, "Efficacies of 5-and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections," Annals of Tropical Medicine and Parasitology, vol. 93, no. 8, pp. 809-812, 1999.
27. N. Valecha, T. Adak, A. K. Bagga et al., "Comparative antirelapse efficacy of CDRI compound 80/53 (Bulaquine) vs primaquine in double blind clinical trial," Current Science, vol. 80, no. 4, pp. 561-563, 2001.
28. K. L. Kristensen and U. B. Dragsted, "Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report," Scandinavian Journal of Infectious Diseases, vol. 46, no. 1, pp. 63-65, 2014.
29. S. Krudsood, N. Tangpukdee, P. Wilairatana et al., "Highdose primaquine regimens against relapse of Plasmodium vivax malaria, "The American Journal of Tropical Medicine and Hygiene, vol. 78, no. 5, pp. 736-740, 2008.
30. E. C. Duarte, L. W. Pang, L. C. Ribeiro, and C. J. Fernandes Fontes, "Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria," The American Journal of Tropical Medicine and Hygiene, vol. 65, no. 5, pp. 471-476, 2001.
31. J. Faucher, A. Bellanger, C. Chirouze, L. Hustache-Mathieu, S. Genton, and B. Hoen, "Primaquine for radical cure of Plasmodiumvivax and Plasmodiumovalemalaria: an observational survey (2008-2010)," Journal of Travel Medicine, vol. 20, no. 2, pp. 134-136, 2013.
32. J. Kim, M. Imwong, A. Nandy et al., "Genetic diversity of Plasmodium vivax in Kolkata, India," Malaria Journal, vol. 5, article 71, 2006.
33. W. E. Collins, "Further understanding the nature of relapse of Plasmodium vivax infection," Journal of Infectious Diseases, vol. 195, no. 7, pp. 919-920, 2007.
34. K. Kirchgatter and H. A. Del Portillo, "Molecular analysis of Plasmodium vivax relapses using the MSP1 molecule as a geneticmarker," Journal of Infectious Diseases, vol. 177, no. 2, pp. 511-515, 1998.
35. B. L. Rice, M. M. Acosta, M. A. Pacheco, and A. A. Escalante, "Merozoite surface protein-3 alpha as a genetic marker for epidemiologic studies in Plasmodium vivax: a cautionary note," Malaria Journal, vol. 12, no. 1, article 288, 2013.
36. A. Maestre, S. Sunil, G. Ahmad et al., "Inter-allelic recombination in the Plasmodium vivax merozoite surface protein 1 gene among Indian and Colombian isolates," Malaria Journal, vol. 3, article 1, pp. 1-6, 2004.
37. M. C. Leclerc, M. Menegon, A. Cligny et al., "Genetic diversity of Plasmodiumvivax isolates fromAzerbaijan, "Malaria Journal, vol. 3, article 40, 2004.
38. E. Schwartz, G. Regev-Yochay, and D. Kurnik, "Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivaxmalaria," The American Journal of Tropical Medicine and Hygiene, vol. 62, no. 3, pp. 393-395, 2000.
39. J. Bennett, B. Pybus, A. Yadava et al., "Primaquine failure and cytochrome P-450 2D6 in plasmodium vivaxmalaria," The New England Journal of Medicine, vol. 369, pp. 1381-1382, 2013.
40. Organization WH, Guidelines for the Treatment of Malaria, World Health Organization, 2006.
41. J.N. Gogtay, N. B. Mali, K. Iyer et al., "Evaluation of cytochrome P450 2D6 phenotyping in healthy adult Western Indians," Indian Journal of Pharmacology, vol. 46, article 266, 2014.